Recent publications published by researchers at the MRC WIMM.
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML.
Wang Z. et al, (2025), Blood
Molecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.
Godfrey AL. et al, (2024), Br J Haematol
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.
Carrelha J. et al, (2024), Nat Immunol, 25, 1007 - 1019
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT. et al, (2024), Blood Adv
Backtracking to the future: unraveling the origins of childhood leukemia.
de Smith AJ. et al, (2024), Leukemia, 38, 416 - 419
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST. et al, (2024), EJHaem, 5, 105 - 116
Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL. et al, (2024), Cancer Res, 84, 211 - 225
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas A. et al, (2024), Blood, 143, 178 - 182
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2024), Br J Haematol, 204, 127 - 135
Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Wang Z. et al, (2024), BLOOD, 144, 2749 - 2751
Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
Wong ZC. et al, (2024), CANCER RESEARCH, 84
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms- All Clones Are Not Equal
Chowdhury O. et al, (2024), BLOOD, 144, 3615 - 3616
The management of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2024), Br J Haematol, 204, 136 - 150